Cannabidiol (Epidiolex)
Small molecule
Also known as GWP42003
Evidence outlook
Approved: Epilepsy, Lennox-Gastaut Syndrome, Dravet Syndrome, Developmental and Epileptic Encephalopathies
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (2)
- Treatment of seizures associated with tuberous sclerosis complex (TSC) in patients 1 year of age and older
- Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
GWPCARE5 NCT02224573 · Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome This is a genuine open-label extension trial: the title explicitly states 'Open Label Extension Study,' and eligibility required participants to have completed the treatment phase of the prior randomized, double-blind, placebo-controlled core studies (NCT02091206, NCT02091375, NCT02224703, NCT02224560, NCT02224690). It used a single group of 681 participants with no randomization, no blinding, and no comparator arm, so it cannot provide comparative evidence on its own. The primary outcomes were mostly safety measures plus descriptive changes in seizure frequency, and no inferential statistical comparison was conducted. Registry: NCT02224573 | 3 | Number of Participants With Any Treatment-emergent Adverse Event (TEAE) Occurring in ≥5% of Participants in Any Treatment Group (up to Week 260); Number of Participants With Clinically Significant Changes in the Indicated Vital Sign Values From the Pre-randomization Baseline of the Core Study at Any Time Post-dose (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Body Mass Index (BMI) (up to Week 260); Number of Participants With Clinically Significant Electrocardiogram (ECG) Values at the Pre-randomization Baseline of the Core Study and at Any Time Post-dose (up to Week 260); Number of Participants With the Indicated Responses to Questions Regarding Suicidal Ideation and Behavior Using the Children's Columbia-Suicide Severity Rating Scale (C-SSRS) at Day 1 and at Any Time Post-dose (up to Week 260); Mean Cannabis Withdrawal Scale Score at End of Taper (EOT), the Post-Taper Safety Call, and at Safety Follow-up (up to Week 260); Mean Pediatric Cannabinoid Withdrawal Scale (PCWS) Score at the End of Treatment, the End of Taper, the Post-Taper Safety Call, and at Safety Follow-up (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Red Blood Cells (RBCs) Values (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Hemoglobin Levels (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Hematocrit Values (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Erythrocyte Mean Corpuscular Volume (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Erythrocyte Mean Corpuscular Hemoglobin (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Platelets, White Blood Cells, Basophils, Eosinophils, Lymphocytes, Monocytes, and Neutrophils (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in the Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Neutrophils in White Blood Cells (WBCs) (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Sodium, Potassium, Blood Urea Nitrogen, Glucose, Calcium, and High-Density Lipoprotein (HDL) Cholesterol (up to week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Creatinine (Jaffe), Creatinine (Enzymatic), and Bilirubin (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Creatinine Clearance (Schwartz) and Creatinine Clearance (Cockcroft-Gault) (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Alkaline Phosphatase, Aspartate Aminotransferase, Alanine Aminotransferase, and Gamma Glutamyl Transferase (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Albumin and Protein (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Prolactin (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Prothrombin Time (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Prothrombin International Normalized Ratio (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Insulin-like Growth Factor-1 (IGF-1) Levels (up to Week 260); Mean Subject/Caregiver Global Impression of Change (S/CGIC) Score (Baseline; up to Week 260); Percent Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Total Seizure Frequency (Baseline; Week 49 to 60, Week 97 to 108, Week 145 to 156, Week 205 to 216, Week 253 to 264, and Last 12 Weeks); Percent Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Drop Seizure Frequency in Participants With Lennox-Gastaut Syndrome (Baseline; Week 49 to 60, Week 97 to 108, Week 145 to 156, Week 205 to 216, and Last 12 Weeks); Percent Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Convulsive Seizure Frequency in Participants With Dravet Syndrome (Baseline; Week 49 to 60, Week 97 to 108, Week 145 to 156, Week 205 to 216, Week 253 to 264, and Last 12 Weeks); Number of Participants With Convulsive and Non-convulsive Seizures Greater Than 30 Minutes in Duration (Status Epilepticus) (Baseline; At last 12 weeks) 2020-09-24 | Number of Participants With Any Treatment-emergent Adverse Event (TEAE) Occurring in ≥5% of Participants in Any Treatment Group (up to Week 260): Dravet Syndrome — Total participants affected by any TEAE: 306 participants; Diarrhoea: 135 participants; Vomiting: 63 participants; Constipation: 20 participants; Nausea: 16 participants; Pyrexia: 124 participants; Fatigue: 39 participants; Upper respiratory tract infection: 78 participants; Nasopharyngitis: 78 participants; Sinusitis: 38 participants; Pneumonia: 35 participants; Ear infection: 35 participants; Influenza: 37 participants; Urinary tract infection: 19 participants; Pharyngitis streptococcal: 26 participants; Gastroenteritis viral: 15 participants; Otitis media: 21 participants; Bronchitis: 15 participants; Viral upper respiratory tract infection: 11 participants; Gastroenteritis: 16 participants; Fall: 22 participants; Laceration: 8 participants; Contusion: 15 participants; Weight decreased: 21 participants; Alanine aminotransferase increased: 37 participants; Aspartate aminotransferase increased: 38 participants; Gamma-glutamyltransferase increased: 32 participants; Decreased appetite: 99 participants; Convulsion: 79 participants; Somnolence: 87 participants; Status epilepticus: 47 participants; Lethargy: 21 participants; Headache: 18 participants; Sedation: 16 participants; Drooling: 11 participants; Abnormal behaviour: 34 participants; Insomnia: 16 participants; Irritability: 26 participants; Aggression: 20 participants; Agitation: 9 participants; Cough: 42 participants; Nasal congestion: 13 participants; Rhinorrhoea: 20 participants; Pneumonia aspiration: 4 participants; Hypoxia: 2 participants | Lennox-Gastaut Syndrome — Total participants affected by any TEAE: 353 participants; Diarrhoea: 140 participants; Vomiting: 107 participants; Constipation: 43 participants; Nausea: 32 participants; Pyrexia: 126 participants; Fatigue: 38 participants; Upper respiratory tract infection: 104 participants; Nasopharyngitis: 58 participants; Sinusitis: 49 participants; Pneumonia: 51 participants; Ear infection: 50 participants; Influenza: 45 participants; Urinary tract infection: 51 participants; Pharyngitis streptococcal: 27 participants; Gastroenteritis viral: 30 participants; Otitis media: 22 participants; Bronchitis: 23 participants; Viral upper respiratory tract infection: 20 participants; Gastroenteritis: 7 participants; Fall: 23 participants; Laceration: 35 participants; Contusion: 25 participants; Weight decreased: 61 participants; Alanine aminotransferase increased: 30 participants; Aspartate aminotransferase increased: 19 participants; Gamma-glutamyltransferase increased: 20 participants; Decreased appetite: 93 participants; Convulsion: 141 participants; Somnolence: 107 participants; Status epilepticus: 42 participants; Lethargy: 34 participants; Headache: 26 participants; Sedation: 27 participants; Drooling: 21 participants; Abnormal behaviour: 23 participants; Insomnia: 40 participants; Irritability: 29 participants; Aggression: 30 participants; Agitation: 19 participants; Cough: 63 participants; Nasal congestion: 46 participants; Rhinorrhoea: 19 participants; Pneumonia aspiration: 22 participants; Hypoxia: 21 participants | Partial signal | link ↗ |
View 5 more trials
GWPCARE6 NCT02544750 · Tuberous Sclerosis Complex, Seizures This was a single-group, open-label extension of the completed double-blind GWEP1521 trial (NCT02544763), with 199 participants continuing into cannabidiol treatment and no concurrent placebo or active-control arm. The primary outcomes were safety measures, so the reported seizure findings were secondary and descriptive rather than a randomized primary-endpoint comparison. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Any Treatment-emergent Adverse Events, Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs (TEAE)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT02544750 | 3 | Number of Participants With Any Treatment-emergent Adverse Events, Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs (TEAE) (OLE Day 1 up to 4 years); Number of Participants With Any TEAE, by Severity (OLE Day 1 up to 4 years) 2021-06-11 | Number of Participants With Any Treatment-emergent Adverse Events, Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs (TEAE) (OLE Day 1 up to 4 years): GWP42003-P (Double-blind Phase) — Any TEAE: 117 Participants; Any treatment-related TEAE: 80 Participants; Any TEAE leading to permanent discontinuation of IMP: 11 Participants; Any treatment-related TEAE leading to permanent discontinuation of IMP: 9 Participants; Any serious TEAE: 38 Participants; Any treatment-related serious TEAE: 7 Participants; Any fatal TEAEs: 1 Participants | Placebo (Double-blind Phase) — Any TEAE: 75 Participants; Any treatment-related TEAE: 60 Participants; Any TEAE leading to permanent discontinuation of IMP: 7 Participants; Any treatment-related TEAE leading to permanent discontinuation of IMP: 7 Participants; Any serious TEAE: 18 Participants; Any treatment-related serious TEAE: 8 Participants; Any fatal TEAEs: 0 Participants | Weak signal | link ↗ |
GWPCARE1 NCT02091375 · Epilepsy, Dravet Syndrome This was a randomized, quadruple-blind, placebo-controlled trial of 120 participants (61 receiving cannabidiol and 59 placebo) using convulsive seizure frequency as its primary clinical endpoint. The primary comparison was met: median seizure frequency fell 38.94% with cannabidiol versus 13.29% with placebo, with p=0.0123. Registry: NCT02091375 | 3 | Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)) 2015-11-26 | Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2) | Reliable signal | link ↗ |
GWPCARE4 NCT02224690 · Epilepsy Participants were randomized to cannabidiol (86) or matching placebo (85), with participants, caregivers, investigators, and outcome assessors blinded. The primary seizure-frequency endpoint was statistically met in favor of cannabidiol (p=0.0135), but no primary-endpoint power calculation is reported in the available sources, so the evidence is graded as moderate rather than strong. Registry: NCT02224690 | 3 | Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)) 2016-03-18 | Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -43.9 percentage change (IQR -69.62 to 1.93) vs Placebo -21.8 percentage change (IQR -45.72 to 1.74) | Partial signal | link ↗ |
GWPCARE3 NCT02224560 · Epilepsy This was a randomized, quadruple-blind, placebo-controlled trial with 225 participants, and its clinical primary endpoint—change in drop-seizure frequency—was statistically significantly better with both cannabidiol doses than placebo. The registry does not report the sample-size or power calculation, so the evidence is considered moderate rather than strong despite the favorable result. Registry: NCT02224560 | 3 | Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)) 2016-05-19 | Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -41.86 percentage change (IQR -72.4 to -1.3) | GWP42003-P 10 mg/kg/Day Dose -37.16 percentage change (IQR -63.8 to -5.6) vs Placebo -17.17 percentage change (IQR -37.1 to 0.9) | Partial signal | link ↗ |
GWPCARE6 NCT02544763 · Epilepsy Patients were randomly assigned to one of two cannabidiol doses or a matching placebo, with patients, caregivers, doctors and assessors blinded. The trial planned 210 patients from a stated power calculation and enrolled 224, and both doses significantly reduced seizures compared with placebo (median reductions of 43.4% and 36.6% versus 20.1%; p=0.0009 and p=0.0018). Registry: NCT02544763 | 3 | Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16) 2019-01-22 | Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): GWP42003-P 25 mg/kg/Day -43.36 percent change (IQR -67.8 to -13.6) | GWP42003-P 50 mg/kg/Day -36.55 percent change (IQR -67 to -5.5) vs Placebo -20.08 percent change (IQR -47.1 to 3.1) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (16)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (3)
What this study did
What this study did
What this study did
Phase 2 (31)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (18)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (5)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2 (1)
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Studied as part of a combination product (1)
Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.
Phase 2/3 (1)
What this study did
Appears in other studies (204)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (17)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (83)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (18)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (44)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Early phase / not applicable (26)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other cannabinoid drugs
Cannabidiol (JZP926), Cannabidiol (Kanbis). Compare all 3 cannabinoid drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Epilepsy: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Cannabidiol (Epidiolex): this drug | Approved | Small molecule | GPR55 / TRPV1 / adenosine transport (multi-target), cannabinoid | Partial signal | NCT02544763: Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): GWP42003-P 25 mg/kg/Day -43.36 percent change (IQR -67.8 to -13.6) | GWP42003-P 50 mg/kg/Day -36.55 percent change (IQR -67 to -5.5) vs Placebo -20.08 percent change (IQR -47.1 to 3.1) NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2) | |
| Brivaracetam | Approved | Small molecule | Synaptic vesicle glycoprotein 2A (SV2A) | Partial signal | No reviewed efficacy summary in this indication | |
| Carbamazepine | Approved | Small molecule | Sodium channels | not yet graded | No reviewed efficacy summary in this indication | |
| Cenobamate (Xcopri) | Approved | Small molecule | Sodium channels + GABA-A receptors | Weak signal | NCT03678753: USA and Rest of World (RoW): Percent Change in PGTC Seizure Frequency Per 28 Days During the Double-blind Treatment Period Relative to Baseline. (Baseline and 22-week Double-blind Treatment Period.): Cenobamate -71.9% (range -100 to 273) vs Placebo -39.61% (range -100 to 211.8) NCT04557085: Median percent change in 28-day focal seizure frequency, 6-week maintenance phase: placebo -25.9% vs cenobamate 100 mg -42.6%, 200 mg -78.3%, 400 mg -100% (all p<.001; Epilepsia 2026) | |
| Clobazam (Onfi) | Approved | Small molecule | GABA-A receptor | Reliable signal | NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100) NCT01160770: Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment (Baseline to month 36): Clobazam 92.3 percentage of drop seizures (range -588 to 100) | |
| Clobazam (Sympazan) | Approved | Small molecule | GABA-A receptor (benzodiazepine site) | not yet graded | No reviewed efficacy summary in this indication | |
| Diazepam (Diastat) | Approved | Small molecule | GABA-A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Diazepam (Valium) | Approved | Small molecule | GABA-A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Diazepam (Valtoco) | Approved | Small molecule | GABA-A receptor | Weak signal | Featured results are non-efficacy only in this race | |
| Divalproex Sodium (Depakote ER) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Eslicarbazepine Acetate (Aptiom) | Approved | Small molecule | Voltage-gated sodium channel | Partial signal | NCT02484001: Primary endpoint (retention time / probability of ESL withdrawal) at 24 months: 0.0638 (95% CI 0.0292-0.1366) in the ESL/ESL group vs 0.0472 (95% CI 0.0180-0.1210) in the CBZ-CR/ESL group NCT00988156: Change From Baseline in Seizure Frequency (Baseline up to Visit 7): Esl (BIA 2-093) 36.6 seizures/month (Standard Deviation 72.47) vs Placebo 62 seizures/month (Standard Deviation 186.19) missed | |
| Ethosuximide | Approved | Small molecule | T-type calcium channel | Reliable signal | NCT00088452: Freedom from treatment failure at 16–20 weeks: 81/154 ethosuximide vs 43/146 lamotrigine, odds ratio 2.66 (95% CI 1.65–4.28; p<0.001); ethosuximide vs valproic acid: 81/154 vs 85/146, with no direct statistical comparison posted. | |
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) | Reliable signal | NCT01713946: Primary 1, response rate (≥50% seizure-frequency reduction) in the maintenance period: placebo 15.1%, low-exposure everolimus 28.2% (p=0.0077), high-exposure everolimus 40.0% (p<0.0001), met for both doses. Primary 2, median percentage reduction in seizure frequency: placebo 14.9%, low exposure 29.3% (p=0.0028), high exposure 39.6% (p<0.0001), met for both doses. | |
| Felbamate | Approved | Small molecule | NMDA receptor (glycine site, antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Fenfluramine (Fintepla) | Approved | Small molecule | Serotonin 5-HT2 receptors | Reliable signal | NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966) | |
| Fosphenytoin | Approved | Small molecule | Voltage-gated sodium channel | Partial signal | No reviewed efficacy summary in this indication | |
| Gabapentin | Approved | Small molecule | α2δ subunit of voltage-gated calcium channels | Partial signal | NCT00007670: VA Cooperative Study 428 (18 centers, 593 elderly patients with new-onset seizures), matching this trial's title/sponsor/design exactly. Primary endpoint (12-month trial retention): early-termination rates were gabapentin 51%, lamotrigine 44.2%, carbamazepine 64.5% (p=0.0002); gabapentin significantly outperformed carbamazepine (p=0.008) but was not shown superior to lamotrigine. Seizure control was similar across all three arms. NCT00603473: Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures (12 weeks): Gabapentin -0.158 ratio (95% CI -0.221 to -0.096) | |
| Ganaxolone | Approved | Small molecule | GABA-A receptor | Partial signal | NCT04391569: Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741) NCT01963208: Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period (Baseline and Week 14): Double Blind: Cohort 2 - Ganaxolone -21.28 Percent change (95% CI -29.6 to -14.29) | Double Blind: Cohort 2 - Placebo -10.25 Percent change (95% CI -20.14 to -1.28) missed | |
| Lacosamide (Vimpat) | Approved | Small molecule | Voltage-gated sodium channels | Reliable signal | NCT00136019: Median % reduction in seizure frequency/28 days: lacosamide 400mg/day -37.3% (p=0.008), 600mg/day -37.8% (p=0.006), vs placebo -20.8%; >=50% responder rates 38.3% (400mg) and 41.2% (600mg) vs 18.3% placebo (p<0.001). NCT02408523: Primary endpoint, time to second PGTC seizure over 24 weeks: hazard ratio 0.540 (95% CI 0.377 to 0.774), p<0.001, lacosamide vs placebo (CT.gov posted results; 49 vs 76 patients with a second PGTC seizure). | |
| Lamotrigine | Approved | Small molecule | Voltage-gated sodium channel | Weak signal | NCT00088452: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Ethosuximide 81/154 | Lamotrigine 43/146 vs Valproic Acid 85/146 missed NCT01431976: Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP) (Week 12 of the Maintenance Phase (up to Study Week 50)): Lamotrigine 7/20 | |
| Levetiracetam (Elepsia XR) | ApprovedUS marketing discontinued | Small molecule | Synaptic vesicle glycoprotein 2A (SV2A) | not yet graded | No reviewed efficacy summary in this indication | |
| Levetiracetam (Keppra XR) | Approved | Small molecule | Synaptic vesicle protein 2A (SV2A) | Partial signal | Featured results are non-efficacy only in this race | |
| Levetiracetam (Keppra) | Approved | Small molecule | Synaptic vesicle protein 2A (SV2A) | Partial signal | NCT00150709: Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline): N159 PBO/LEV -66.4 percentage of change (IQR -90 to -22.3) | N159 LEV/LEV -47.8 percentage of change (IQR -76.2 to -25.4) | N01010+N151 LEV/LEV -66.4 percentage of change (IQR -93.6 to -5.6) NCT00615615: Partial-onset seizure frequency per week during the 14-week treatment period (primary endpoint): 26.8% greater reduction with levetiracetam vs placebo (p=0.0002, 95% CI 14.0-37.6%); 50%-responder rate 44.6% (45/101) LEV vs 19.6% (19/97) placebo (p=0.0002). | |
| Lorazepam | Approved | Small molecule | GABA-A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Midazolam (Nayzilam) | Approved | Small molecule | GABA-A receptor, GABA-A receptor (benzodiazepine site) | Reliable signal | NCT01390220: Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67 NCT01999777: Number of Participants That Were Seizure-free (6 hours): USL261 17/31 vs Placebo 12/31 missed | |
| Oxcarbazepine (Oxtellar XR) | Approved | Small molecule | Voltage-gated sodium channel | Partial signal | Featured results are non-efficacy only in this race | |
| Oxcarbazepine (Trileptal) | Approved | Small molecule | Voltage-gated sodium channel | Weak signal | NCT00050934: Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047. | |
| Perampanel (Fycompa) | Approved | Small molecule | AMPA receptor (antagonist) | Weak signal | NCT01393743: Core study: median percent change in PGTC seizure frequency per 28 days, perampanel -76.5% vs placebo -38.4%, median difference -30.8 (95% CI -45.5 to -15.2), p=0.0001; 50% responder rate in maintenance 64.2% vs 39.5%, p=0.0019 (n=81 each) (CT.gov posted results). NCT00699582: Median percent change in 28-day seizure frequency: placebo -9.7%, perampanel 8 mg -30.5% (p<0.001), 12 mg -17.6% (p=0.011); 50% responder rate 14.7%, 33.3% (p=0.002) and 33.9% (p<0.001) (Study 305, Epilepsia 2013). | |
| Phenobarbital Sodium Injection (Sezaby) | Approved | Small molecule | GABA-A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Phenytoin | Approved | Small molecule | Voltage-gated sodium channels | not yet graded | No reviewed efficacy summary in this indication | |
| Pregabalin | Approved | Small molecule | α2δ subunit of voltage-gated calcium channels | Weak signal | NCT01747915: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase (Day 1 up to Week 12): Pregabalin 5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day 1.17 Seizure per 28 days (Standard Error 0.097) | Pregabalin 10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day 1.13 Seizure per 28 days (Standard Error 0.095) vs Placebo 1.14 Seizure per 28 days (Standard Error 0.098) missed | |
| Primidone | Approved | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Rufinamide | Approved | Small molecule | Voltage-gated sodium channel | Partial signal | NCT00334958: Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis). | |
| Stiripentol | Approved | Small molecule | GABA-A receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Tiagabine | Approved | Small molecule | GABA transporter (uptake carrier) | not yet graded | No reviewed efficacy summary in this indication | |
| Topiramate (Eprontia) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Topiramate (Qudexy XR) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | Reliable signal | NCT01142193: Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100) | |
| Topiramate (Topamax Sprinkle) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Topiramate (Topamax) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | Partial signal | NCT00113815: Primary endpoint, median % reduction from baseline in daily partial-onset-seizure rate (video-EEG): topiramate 25 mg/kg 20.4% vs placebo 13.1% (p=0.97); 15 mg/kg dose p=0.97 vs placebo; 5 mg/kg dose p=0.91 vs placebo -- no dose significantly better than placebo. missed NCT00236756: Topiramate add-on in Lennox-Gastaut syndrome: median percentage reduction from baseline in average monthly seizure rate 14.8% with topiramate versus a -5.1% increase with placebo; a >=50% reduction from baseline in major seizures (drop attacks and tonic-clonic seizures) was reached by 33% of the topiramate group versus 8% of the control group. | |
| Topiramate (Trokendi XR) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Valproate | ApprovedUS marketing discontinued | Small molecule | GABAergic neurotransmission | Partial signal | NCT00004817: Phase III NINDS trial (Temkin et al.): valproate did not reduce early or late post-traumatic seizure rates vs phenytoin control, and showed a trend toward higher mortality (13.4% vs 7.2%). missed | |
| Vigabatrin (Sabril) | Approved | Small molecule | GABA transaminase (GABA-T) | Partial signal | NCT02849457: Cognitive Assessment Scores and Developmental Impact (24 months): Delayed Vigabatrin (Placebo) 83.9 score on a scale ± 17.3 vs Early Vigabatrin 80.9 score on a scale ± 15.6 vs Watchful Waiting (Control Group) 97.3 score on a scale ± 16.9 vs Watchful Waiting (Open Label Vigabatrin) 85.0 score on a scale ± 21.6; p=0.8681 (Delayed Vigabatrin (Placebo) vs Early Vigabatrin) missed | |
| Vigabatrin (Vigafyde) | Approved | Small molecule | GABA transaminase (GABA-T) | not yet graded | No reviewed efficacy summary in this indication | |
| Zonisamide (Zonegran) | Approved | Small molecule | Voltage-gated sodium channels | Weak signal | Featured results are non-efficacy only in this race | |
| Zonisamide (Zonisade) | Approved | Small molecule | Voltage-gated sodium and T-type calcium channels | not yet graded | No reviewed efficacy summary in this indication | |
| Azetukalner | Phase 3 | Small molecule | Kv7 potassium channel | Reliable signal | NCT05614063: Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4% | |
| Bexicaserin | Phase 3 | Small molecule | Serotonin 5-HT2C receptor (agonist) | Partial signal | NCT05364021: Primary endpoint, median percentage change in countable motor seizures over the treatment period: bexicaserin -59.8% (n=35) vs placebo -17.4% (n=9), difference 42.4%, p = .0538 (not statistically significant) (PACIFIC, Epilepsia 2026). missed | |
| Carisbamate | Phase 3 | Small molecule | Voltage-gated sodium channel | Partial signal | NCT00425282: Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results). NCT00433667: Primary endpoint, responder rate (at least 50% reduction in partial-onset seizure frequency, double-blind phase vs baseline): carisbamate 400 mg 23.8% and 200 mg 23.1% vs placebo 21.3%; difference 2.48 points (95% CI -6.04 to 11), P = 0.553 (400 mg) and 1.84 points (95% CI -6.58 to 10.26), P = 0.637 (200 mg) (pre-specified CMH tests, EU Clinical Trials Register results). missed | |
| Clemizole (EPX-100) | Phase 3 | Small molecule | Histamine H1 receptor, Serotonin receptors (5-HT) | not yet graded | No reviewed efficacy summary in this indication | |
| Diazepam (Libervant) | Phase 3 | Small molecule | GABA-A receptor | Weak signal | Featured results are safety only in this race | |
| Elsunersen | Phase 3 | RNA / oligonucleotide | SCN2A (antisense knockdown) | Partial signal | NCT05737784: Part A (randomized 3:1, sham-controlled, 9 patients): 77% placebo-adjusted seizure reduction from baseline (p=0.015) (Praxis, 2026-04-06). | |
| RAP-219 | Phase 3 | Small molecule | AMPA receptor (TARP γ8-dependent) | Weak signal | NCT06377930: Primary endpoint met: 85.2% of patients achieved ≥30% reduction in long episodes (LEs) from baseline (p<0.0001); 72.0% achieved ≥50% reduction in clinical seizures (p<0.0001) | |
| Relutrigine | Phase 3 | Small molecule | Voltage-gated sodium channel (persistent current) | not yet graded | No reviewed efficacy summary in this indication | |
| Staccato Alprazolam | Phase 3 | Small molecule | GABA-A receptor | Reliable signal | NCT03478982: 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8) | |
| Vormatrigine | Phase 3 | Small molecule | Voltage-gated sodium channel (NaV1.2 / NaV1.6) | Partial signal | NCT06999902: Primary success measure (reduction in focal seizure frequency over 12 weeks versus placebo) not met, per Praxis; the secondary 50% responder rate was met. The company disclosed no numbers. missed | |
| YCJ-01 | Phase 3 | Botanical | Cannabinoids (full-spectrum cannabis extract) | not yet graded | No reviewed efficacy summary in this indication | |
| Cannabidiol (JZP926) | Phase 2/3 | Small molecule | Cannabidiol (CBD) modulates multiple targets, including the transient receptor potential vanilloid 1 (TRPV1) and the orphan G-protein-coupled receptor GPR55, cannabinoid | not yet graded | No reviewed efficacy summary in this indication | |
| Opakalim | Phase 2/3 | Small molecule | Kv7 potassium channel | Weak signal | NCT06425159: Closed early with 27 subjects: median time to second generalized tonic-clonic seizure 141 days with opakalim vs 47 days with placebo; no formal statistical test reported (Biohaven, 2026-05-26). | |
| ABS-1230 | Phase 2 | Small molecule | KCNT1 (KNa1.1/Slack) channel | not yet graded | No reviewed efficacy summary in this indication | |
| AV078 | Phase 2 | Small molecule | mTORC1 (mammalian target of rapamycin complex 1) (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| BMB-101 | Phase 2 | Small molecule | Serotonin 5-HT2C receptor (biased agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Huperzine A (SPN-817) | Phase 2 | Small molecule | Acetylcholinesterase | Weak signal | NCT03156439: Participants were given the experimental treatment twice a day, with the dose increased every two to three days until a maximum daily dose of 2.5 mg was reached. Participants tolerated the treatment well, with mild to moderate, transient and non-dose-limiting adverse events. |
Large race: only the 63 furthest-along competitors are listed; 10 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
Upcoming events
(22 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Cannabidiol (Epidiolex) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.